EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases

Mika Horie iD, Tamio Okimoto iD, Yusuke Okada, Masaya Inoue, Shintaro Shimizu, Hirotoki Tsuda, Kojiro Hata, Takae Okuno, Yoshihiro Amano, Mika Nakao, Kazuhisa Nakashima iD, Megumi Hamaguchi iD und 1 weitere

Respirology Case Reports · 2026-11 · 14 (11)

DOI: 10.1002/rcr2.70804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respirology Case Reports, online erschienen am 02.11.2026. Verfasst von Mika Horie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with malignant lymphoma receiving anti‐CD20 antibody therapy are at high risk of persistent coronavirus disease 2019 (COVID‐19), with no established standard treatment. We report three cases of persistent COVID‐19 in patients with follicular lymphoma who responded clinically after switching to ensitrelvir following the failure of remdesivir‐based treatment. Each patient had multiple relapses and an inadequate response to remdesivir but achieved symptom resolution with ensitrelvir. These cases suggest that switching to an antiviral with a different mechanism of action may be an effective therapeutic strategy for immunocompromised patients when initial antiviral therapies fail.

Schlagwörter

Stichwörter der Autor:innen

coronavirus disease 2019 (COVID‐19)ensitrelvirimmunocompromised hostmalignant lymphomapersistent COVID‐19

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine Shimane University Faculty of Medicine Izumo Shimane Japan.
  • Department of Hematology Shimane University Hospital Izumo Japan.

ORCID-Profile: Mika Horie, Tamio Okimoto, Kazuhisa Nakashima, Megumi Hamaguchi

Zitieren

APA

Horie, M., Okimoto, T., Okada, Y., Inoue, M., Shimizu, S., Tsuda, H., Hata, K., Okuno, T., Amano, Y., Nakao, M., Nakashima, K., Hamaguchi, M., & Isobe, T. (2026). Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases. Respirology Case Reports, 14(11). https://doi.org/10.1002/rcr2.70804

Vancouver

Horie M, Okimoto T, Okada Y, Inoue M, Shimizu S, Tsuda H, et al. Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases. Respirology Case Reports. 2026;14(11). doi:10.1002/rcr2.70804

BibTeX
@article{Horie2026,
  author = {Horie, Mika and Okimoto, Tamio and Okada, Yusuke and Inoue, Masaya and Shimizu, Shintaro and Tsuda, Hirotoki and Hata, Kojiro and Okuno, Takae and Amano, Yoshihiro and Nakao, Mika and Nakashima, Kazuhisa and Hamaguchi, Megumi and Isobe, Takeshi},
  title = {Persistent Coronavirus Disease 2019 ( COVID ‐19) in Patients With Malignant Lymphoma Treated With Anti‐ CD20 Antibodies Who Responded to Ensitrelvir: A Report of Three Cases},
  journal = {Respirology Case Reports},
  year = {2026},
  volume = {14},
  number = {11},
  doi = {10.1002/rcr2.70804}
}
Kostenlos starten →